Cocrystal Pharma Inc (COCP) 0.7800 $COCP Cocrystal

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cocrystal Pharma Inc (COCP) 0.7800 $COCP

Cocrystal Pharma elects Douglas Mayers MD as CMO
M2 - Fri Sep 25, 3:36AM CDT
Bio-pharmaceutical company Cocrystal Pharma (OTC BB:COCP) revealed on Thursday the election of Douglas Mayers MD as its chief medical officer (CMO) to advance its HCV, influenza and norovirus programmes.

Cocrystal Pharma Announces Appointment of Douglas Mayers, M.D., as Chief Medical Officer
Marketwired - Thu Sep 24, 6:00AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a bio-pharmaceutical company dedicated to creating novel small molecules for viral infections and liver diseases, today announced the appointment of Douglas Mayers, M.D., to the position of chief medical officer (CMO). This appointment reflects Cocrystal's continued growth as the Company prepares to advance its HCV, influenza and norovirus programs.
OPK: 8.90 (+0.26)

Cocrystal Pharma names Jeffrey Meckler CEO
M2 - Tue Sep 22, 3:06AM CDT
The board of directors of Cocrystal Pharma (OTCBB:COCP), a bio-pharmaceutical company, disclosed on Monday the addition of Jeffrey Meckler as its chief executive officer (CEO) with effect from 1 October 2015.

Cocrystal Pharma Appoints Jeffrey Meckler as Chief Executive Officer
Marketwired - Mon Sep 21, 7:02AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a bio-pharmaceutical company focused on developing novel antiviral therapeutics for human diseases, today announced that its Board of Directors has appointed board member Jeffrey Meckler to the position of Chief Executive Officer (CEO), effective October 1st. Mr. Meckler had been serving as Cocrystal Pharma's Interim CEO since March 31, 2015.

Nasopharyngitis (Common Cold) Pipeline Review, H2 2015 - 5 Companies & 11 Drug Profiles
M2 - Fri Sep 04, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jrkmc3/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Charleston Laboratories, Inc. - Cocrystal Pharma, Inc. - Neos Therapeutics, Inc. - Orbis Biosciences, Inc. - Vernalis Plc Drug Profiles - (chlorpheniramine maleate codeine) - Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - CCP-05 - CCP-06 - CCP-07 - CCP-08 - CLAT-313 - guaifenesin ER - Small Molecule for Cough and Cold - Small Molecule to Inhibit MAPK13 for Asthma and Cold - Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold For more information visit http://www.researchandmarkets.com/research/jr...haryngitis
NEOS: 18.69 (-0.57)

H5N1 Infection (Avian Influenza) Pipeline Review 2015 - 42 Companies & 59 Drug Profiles
M2 - Fri Jul 31, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/spx39q/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Akshaya Bio Inc. - AlphaVax, Inc. - Antigen Express, Inc. - Aphios Corporation - Aprogen, Inc. - BioDiem Ltd - CEL-SCI Corporation - Cocrystal Pharma, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Gemmus Pharma Inc. - GlaxoSmithKline Plc - Green Cross Corporation - Hemispherx Biopharma, Inc. - iBio, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Kineta, Inc. - Medicago Inc. - Medigen Biotechnology Corporation - Microgen Scientific Industrial Company for Immunobiological Medicines - Myelo Therapeutics GmbH - NanoBio Corporation - Nanotherapeutics, Inc. - NanoViricides, Inc. - NewLink Genetics Corporation - Novartis AG - OPKO Health, Inc. - PaxVax - PDS Biotechnology Corporation - PeptiDream Inc. - Protein Sciences Corporation - REPLICor Inc. - SIGA Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/sp..._infection
JNJ: 95.37 (+0.29), INO: 6.16 (+0.20), EBS: 30.49 (+0.77), CVM: 0.72 (-0.02), OPK: 8.90 (+0.26), NLNK: 34.31 (+1.42), IBIO: 0.68 (unch), NNVC: 1.35 (-0.05), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)

IDI Management Fires Back Against Blog Post
at The Street - Wed Jul 22, 11:32AM CDT
Executives say investor Philip Frost supports them and the company.
YHOO: 32.52 (+0.15), IDI: 7.17 (-0.10), EFX: 105.48 (+0.78)

Cocrystal Pharma Names Walt Addison Linscott, Esq. New General Counsel and Corporate Secretary
Marketwired - Wed Jul 15, 8:25AM CDT
Cocrystal Pharma, Inc. (OTCQB:COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today the appointment of Walt Addison Linscott, Esq. as General Counsel and Corporate Secretary.
ABT: 41.89 (+0.73)

Cocrystal Pharma to Present at Jefferies 2015 Global Healthcare Conference
Marketwired - Thu May 28, 8:27AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it will be presenting at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 from 12:30 p.m. to 1:00 p.m. at the Grand Hyatt in New York, New York.

Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 17.24 (+0.05), ARWR: 5.89 (+0.13), ACHN: 7.57 (-0.10), CNAT: 4.21 (-0.06), ANAC: 115.06 (+2.13), ABBV: 55.64 (-0.40), BMY: 61.44 (+0.93), CELGZ: 1.74 (+0.04)

Solid Pipeline and Big Player Backing: Cocrystal Pharma Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Mon Apr 27, 6:00AM CDT
Cocrystal Pharma Inc. (OTCQB: COCP) a Washington-State based pharmaceutical company working to develop antiviral therapeutics as treatments for serious and/or chronic viral diseases, expects to begin clinical studies on several of its antiviral therapeutic treatments in 2015. The company has several drugs in various stages of development for the treatment of Hepatitis C, Influenza, Norovirus, Dengue Fever and others.

InsiderInsights.com Daily Round Up 4/23/15: GE, OMN, COCP, AGCO
InsiderInsights - at Seeking Alpha - Fri Apr 24, 7:53AM CDT

STFC: 24.13 (-0.01), GE: 28.07 (+0.04), OMN: 6.60 (+0.01), AGCO: 47.01 (-0.57), SAM: 228.44 (+2.75), AMGN: 149.59 (-0.31), ILMN: 147.77 (+7.40), NXRT: 13.52 (-0.07), BDCV: 4.68 (-0.01), MPWR: 54.99 (-0.31), WCIC: 23.25 (-0.29), ADS: 280.12 (+0.71), KMX: 58.77 (-1.19), SVVC: 8.55 (+0.10), ALNY: 83.16 (+0.88), GRPN: 3.87 (+0.01), UCTT: 5.82 (-0.06)

Cocrystal Pharma - Overhyped Biotech Or The Next Pharmasset?
Greg Buch - at Seeking Alpha - Tue Apr 07, 10:19AM CDT


Opko and its CEO Dr. Phillip Frost Add MabVax to Their Portfolios
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
CORAL GABLES, FL / ACCESSWIRE / April 6, 2015 / Holding companies invest in the securities of other companies all the time aiming to increase shareholder value. There are hits and there are misses, as with all investments. But Opko Health (NYSE: OPK) has been on such a hot streak in this game especially in the last few months that even relatively small deals deserve attention. Its latest move - both for Opko and for Frost's personal investment trust - is to be part of a $12M private placement into MabVax Therapeutics (OTCQB: MBVX).
OPK: 8.90 (+0.26), PFE: 33.24 (+0.15), JUNO: 48.64 (+0.84), NVCN: 4.24 (+0.18)

InsiderInsights.com Daily Round Up 3/27/15: COCP, GPRO, SJW, AGCO
InsiderInsights - at Seeking Alpha - Sun Mar 29, 12:55PM CDT

GPRO: 29.08 (+1.48), HCOM: 22.59 (+0.32), DPLO: 26.65 (+1.93), AGCO: 47.01 (-0.57), ENV: 32.74 (+0.16), LPI: 13.40 (-0.56), GOOG: 643.61 (+4.45), NOW: 74.42 (+1.40), ARMK: 30.89 (-0.03), JAZZ: 133.40 (+0.37), GLF: 8.79 (+0.43), SJW: 32.00 (-0.44), JGW: 5.77 (-0.10), ALCO: 43.48 (+0.32), FI: 17.90 (+0.22), CRM: 75.25 (+0.16)

Opko's Frost Inks Levon Deal with Israel's SciVac, a Hint for the Next Merger?
ACCESSWIRE - Fri Mar 20, 10:30AM CDT
NEW YORK, NY / ACCESSWIRE / March 20, 2015 / On September 11 last year, a little-known Israeli financial magazine called Globes came out with a report that Dr. Phillip Frost, Chairman and CEO of Opko Health (NYSE:OPK), and then Chairman of Teva Pharmaceuticals (NYSE:TEVA), was interested in moving a private Israeli biotech called SciVac, 45% owned by Opko, into a corporate shell and making it public.
OPK: 8.90 (+0.26), TEVA: 58.96 (-0.28)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 38

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 301

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 105

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 23

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 5

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 92

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading

Top 5 Most Recently Viewed Articles

Customers Bancorp, Inc. Faces Class Action Lawsuit

Updated Category News Views 179

Introduction to the Class Action Lawsuit Against Customers Bancorp Recently, Customers Bancorp, Inc. found itself at the center of a significant legal challenge. A securities class action lawsuit has been initiated in federal court on behalf of investors who purchased or acquired shares of Customers Bancorp, Inc. (NYSE: CUBI) during a specific time frame. This action...

Continue Reading
Projected Growth in the Aluminum Beverage Can Industry

Updated Category News Views 238

Exploring the Future of the Aluminum Beverage Can Market As the aluminum beverage can industry steers toward a monumental future, it's evident that the market has grown significantly, evolving to meet the rising demand for sustainable and practical packaging solutions. With a valuation of US$ 36.95 billion in 2024, projections indicate a remarkable increase to US$ 61.12...

Continue Reading
Cybersecurity Initiative Launches for Global Nonprofit Protection

Updated Category News Views 87

Global Leaders Unite for Nonprofit Cybersecurity Influential figures from various sectors gathered at the historic Peace Palace to advocate for better cybersecurity within the nonprofit sector. This initiative, known as 'BEYOND125, Securing Our World's Digital Future,' is focused on tackling significant cybersecurity challenges faced by millions of organizations around...

Continue Reading
Guarda Wallet's Gas-Free USDT Revolution on Tron

Updated Category News Views 44

The Frictionless Future of USDT on the Tron Network You know, it seems like every few months we hear about some innovation that's going to 'revolutionize' crypto transactions. But here's something that's actually shifting the gears—a practical workaround for a typical problem faced by the average Joe trading in stablecoins. Welcome to Guarda Wallet's gas-free...

Continue Reading
Ultragenyx and Mereo BioPharma Stocks Face Significant Decline

Updated Category News Views 130

Overview of Current Situation Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) saw their stock values significantly drop recently, causing concern among investors. The decline comes in light of new developments from their ongoing clinical trials for a drug targeting a rare genetic disorder. What Unfolded? The duo announced updates...

Continue Reading